Search research articles
Contact Us
Filters
Showing results (1-10 of 8) with videos related to
Page
of 1
Sort By:
Revista Espanola De Medicina Nuclear
|
October 1, 2005
[Recurrent signet-ring cell gastric carcinoma evidenced by FDG-PET]
G Ruiz-Hernández, R C Delgado-Bolton, M J Rubio-Pérez, et al.
Gynecologic Oncology
|
January 22, 2022
Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis
A Poveda, S Lheureux, N Colombo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 1, 2024
The efficacy and safety of mirvetuximab soravtansine in FRα-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial
A Alvarez Secord, S N Lewin, C G Murphy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 5, 2023
Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial
E Pujade-Lauraine, F Selle, G Scambia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 11, 2025
Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer
P Harter, F Trillsch, A Okamoto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 11, 2024
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial
P Harter, C Marth, M-A Mouret-Reynier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 16, 2024
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial
B J Monk, M P Barretina-Ginesta, B Pothuri, et al.
British Journal of Cancer
|
February 9, 2023
INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line
N Colombo, A Gadducci, J Sehouli, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 8) with videos related to
Sort By:
Page
of 1
Revista Espanola De Medicina Nuclear
|
October 1, 2005
[Recurrent signet-ring cell gastric carcinoma evidenced by FDG-PET]
G Ruiz-Hernández, R C Delgado-Bolton, M J Rubio-Pérez, et al.
Gynecologic Oncology
|
January 22, 2022
Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis
A Poveda, S Lheureux, N Colombo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 1, 2024
The efficacy and safety of mirvetuximab soravtansine in FRα-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial
A Alvarez Secord, S N Lewin, C G Murphy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 5, 2023
Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial
E Pujade-Lauraine, F Selle, G Scambia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 11, 2025
Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer
P Harter, F Trillsch, A Okamoto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 11, 2024
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial
P Harter, C Marth, M-A Mouret-Reynier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 16, 2024
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial
B J Monk, M P Barretina-Ginesta, B Pothuri, et al.
British Journal of Cancer
|
February 9, 2023
INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line
N Colombo, A Gadducci, J Sehouli, et al.
Page
of 1